Ex vivo efficacy of 0.3% gemifloxacin (GFX) against MRSA-induced keratitis was evaluated.
GFX was the most efficient fluoroquinolone assayed in vitro.
Ex vivo results predicted that GFX may be an effective topical therapy.
Dose–response efficacy showed good performance at lower concentrations.
The ex vivo model has been enabled to mimic in vivo bacterial infection.